Laakso Maija-Liisa, Lindblom Niki, Leinonen Lea, Kaski Markus
Rinnekoti Foundation, Sleep Research Center, Kumputie 1, FIN-02980 Espoo, Finland.
Sleep Med. 2007 Apr;8(3):222-39. doi: 10.1016/j.sleep.2006.09.006. Epub 2007 Mar 23.
: We studied whether the endogenous melatonin patterns in adult patients with developmental brain disorders have any role in response to exogenous melatonin given as a sleep-promoting medicine.
: Participants included 15 adults (18-60 years, five females) with developmental brain disorders of varying etiologies, motor handicaps, and long-term history of sleep problems. According to the 24-h patterns of serum melatonin, patients were divided into two subgroups: lower and higher secretors. The pretreatment sleep disorder was characterized by a structured interview, 24-h ambulatory polysomnography and 7-day wrist actigraphy. Patients received 1, 3, or 6mg fast-release melatonin tablets, each for 4 weeks in increasing order, at a constant time of 30min before the desired sleep onset. Similarly, placebos with different codes were given during 3x4 weeks. The 7-day actigraphy was repeated at the end of each drug period. Outcome measures were six different parameters of non-parametric circadian rhythm analysis. Drug effects and 40 confounding/modulating factors were evaluated by applying two-level regression analyses with co-variables.
: Exogenous melatonin decreased the fragmentation of the rest-activity rhythm, increased the day/night ratio of activity and advanced the onset of rest period. The effects on fragmentation and day/night ratio were more pronounced in the lower than higher secretors of melatonin. Other contributing factors in the drug effects were blindness and some features of the original sleep disorder (disrupted cyclicity of the sleep architecture in polysomnography or reported daytime somnolence).
: Exogenous melatonin consolidated the fragmented rest-activity in about half of the patients. Low endogenous serum melatonin levels at night predicted improvement by the drug. Higher doses were not more effective than the lowest dose.
我们研究了患有发育性脑障碍的成年患者体内内源性褪黑素模式在作为助眠药物给予外源性褪黑素时是否起作用。
参与者包括15名成年患者(18至60岁,5名女性),患有不同病因的发育性脑障碍、运动障碍以及长期睡眠问题史。根据血清褪黑素的24小时模式,患者被分为两个亚组:低分泌者和高分泌者。通过结构化访谈、24小时动态多导睡眠图和7天腕部活动记录仪对治疗前的睡眠障碍进行特征描述。患者分别接受1毫克、3毫克或6毫克速释褪黑素片,每次按递增顺序服用4周,在期望入睡时间前30分钟的固定时间服用。同样,在3×4周期间给予不同编码的安慰剂。在每个药物治疗期结束时重复进行7天的活动记录仪监测。结果指标是非参数昼夜节律分析的六个不同参数。通过应用带有协变量的二级回归分析评估药物效果和40个混杂/调节因素。
外源性褪黑素减少了静息 - 活动节律的碎片化,增加了活动的昼夜比,并提前了休息期的开始。褪黑素低分泌者比高分泌者对碎片化和昼夜比的影响更明显。药物效果的其他影响因素是失明和原始睡眠障碍的一些特征(多导睡眠图中睡眠结构的周期性紊乱或报告的日间嗜睡)。
外源性褪黑素使约一半患者的碎片化静息 - 活动得到巩固。夜间内源性血清褪黑素水平低预示着药物治疗有效。高剂量并不比最低剂量更有效。